GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM Vaccine Co Ltd (HKSE:06660) » Definitions » LT-Debt-to-Total-Asset

AIM Vaccine Co (HKSE:06660) LT-Debt-to-Total-Asset : 0.08 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is AIM Vaccine Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AIM Vaccine Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.08.

AIM Vaccine Co's long-term debt to total assets ratio increased from Dec. 2022 (0.04) to Dec. 2023 (0.08). It may suggest that AIM Vaccine Co is progressively becoming more dependent on debt to grow their business.


AIM Vaccine Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for AIM Vaccine Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM Vaccine Co LT-Debt-to-Total-Asset Chart

AIM Vaccine Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
0.02 0.01 0.03 0.04 0.08

AIM Vaccine Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 0.03 - 0.04 0.08 0.08

AIM Vaccine Co LT-Debt-to-Total-Asset Calculation

AIM Vaccine Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=622.764/7943.017
=0.08

AIM Vaccine Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=622.764/7943.017
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM Vaccine Co  (HKSE:06660) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


AIM Vaccine Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of AIM Vaccine Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM Vaccine Co (HKSE:06660) Business Description

Traded in Other Exchanges
N/A
Address
91 Jianguo Road, 25th Floor, Building A, Chaoyang, Beijing, CHN
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development, manufacturing and commercialization. The products available for sale mainly include Recombinant HBV vaccine, Human rabies vaccine, HFRS Vaccine, hepatitis A vaccine (human diploid cell), Group A, C, Y and W135 MPSV, mumps vaccine, freeze-dried human rabies vaccine (Vero cell) and ACYW135 meningococcal polysaccharide vaccine. Geographically, the company generates all of its revenues in the PRC.
Executives
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Shang Yin Xing Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Zi Ben Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Shi Bei Lun Qu Guo You Zi Ben Yun Ying You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Bao Shui Qu Kong Gu You Xian Gong Si 2101 Beneficial owner
Yong Zhou Qing Teng Mao Yi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Li Lihua 2201 Interest of corporation controlled by you
Shang Hai Xun Jing Qi Ye Guan Li Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Zhu Hai Tong Dao Ming Tian Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Mei Hua Sheng Wu Ke Ji Ji Tuan Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
La Sa Mei Hua Sheng Wu Tou Zi Kong Gu You Xian Gong Si 2101 Beneficial owner
Xi Zang Dong Fang Zhi Hui Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shen Yang Qian Qian Qi Ye Guan Li Zi Xun You Xian Gong Si 2101 Beneficial owner

AIM Vaccine Co (HKSE:06660) Headlines

No Headlines